Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The FDA is widening its scrutiny of telehealth companies selling compounded GLP-1 drugs, and a closer look by STAT’s Katie Palmer shows the industry’s supply chain is far more concentrated than its marketing suggests.Â
Also, regulators are rolling out a new real-time adverse event system, biotech leaders warn about U.S. competitiveness, and Aldeyra’s complaints about short sellers raise a familiar investor red flag…Continue to STAT+ to read the full story…